Neoadjuvant Combo Immunotherapy Effective in Resectable Melanoma

In resectable clinical stage 3 or oligometastatic stage 4 melanoma, neoadjuvant treatment with combination relatlimab and nivolumab (Opdualag, Bristol Myers Squibb) is effective. Among 30 patients, there was a 57% pathologic complete response rate and 70% overall pathologic response rate.

Read this Next
About UsOur ProductsCustom SolutionsHow it’s SoldOur ResultsDeliveryContact UsBlogPrivacy PolicyFAQ